Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

B. I. Rini; N. M. Tannir; B. Escudier; D. F. McDermott; M. O. Grimm; C. Porta; T. Powles; C. K. Kollmannsberger; H. P. Gurney; S. S. Tykodi; M. Harrison; D. Y. C. Heng; V. Grünwald; T. K. Choueiri; S. Mekan; M. B. McHenry; H. J. Hammers; R. J. Motzer; S. George

doi:10.1093/annonc/mdy283.084

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

B. I. Rini, N. M. Tannir, B. Escudier, D. F. McDermott, M. O. Grimm, C. Porta, T. Powles, C. K. Kollmannsberger, H. P. Gurney, S. S. Tykodi, M. Harrison, D. Y. C. Heng, V. Grünwald, T. K. Choueiri, S. Mekan, M. B. McHenry, H. J. Hammers, R. J. Motzer, S. George

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

13 Downloads (Pure)

Original language	English
Pages (from-to)	viii309-viii310
Number of pages	2
Journal	Annals of Oncology
Volume	29
Issue number	Supplement 8
DOIs	https://doi.org/10.1093/annonc/mdy283.084
Publication status	Published - 1 Oct 2018
Event	43rd European Society for Medical Oncology Congress (ESMO 2018) - Munich, Germany Duration: 19 Oct 2018 → 23 Oct 2018

Bibliographical note

Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Access to Document

10.1093/annonc/mdy283.084

Publisher version (open access)Final published version, 113 KBLicence: CC BY-NC-ND

Cite this

Rini, B. I., Tannir, N. M., Escudier, B., McDermott, D. F., Grimm, M. O., Porta, C., Powles, T., Kollmannsberger, C. K., Gurney, H. P., Tykodi, S. S., Harrison, M., Heng, D. Y. C., Grünwald, V., Choueiri, T. K., Mekan, S., McHenry, M. B., Hammers, H. J., Motzer, R. J., & George, S. (2018). Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. Annals of Oncology, 29(Supplement 8), viii309-viii310. https://doi.org/10.1093/annonc/mdy283.084

@article{0b957d2d33094b8f8bf7ac837f742add,

title = "Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214",

author = "Rini, {B. I.} and Tannir, {N. M.} and B. Escudier and McDermott, {D. F.} and Grimm, {M. O.} and C. Porta and T. Powles and Kollmannsberger, {C. K.} and Gurney, {H. P.} and Tykodi, {S. S.} and M. Harrison and Heng, {D. Y. C.} and V. Gr{\"u}nwald and Choueiri, {T. K.} and S. Mekan and McHenry, {M. B.} and Hammers, {H. J.} and Motzer, {R. J.} and S. George",

note = "Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.; 43rd European Society for Medical Oncology Congress (ESMO 2018) ; Conference date: 19-10-2018 Through 23-10-2018",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy283.084",

language = "English",

volume = "29",

pages = "viii309--viii310",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "OXFORD UNIV PRESS INC",

number = "Supplement 8",

}

Rini, BI, Tannir, NM, Escudier, B, McDermott, DF, Grimm, MO, Porta, C, Powles, T, Kollmannsberger, CK, Gurney, HP, Tykodi, SS, Harrison, M, Heng, DYC, Grünwald, V, Choueiri, TK, Mekan, S, McHenry, MB, Hammers, HJ, Motzer, RJ & George, S 2018, 'Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214', Annals of Oncology, vol. 29, no. Supplement 8, pp. viii309-viii310. https://doi.org/10.1093/annonc/mdy283.084

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. / Rini, B. I.; Tannir, N. M.; Escudier, B. et al.
In: Annals of Oncology, Vol. 29, No. Supplement 8, 01.10.2018, p. viii309-viii310.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc)

T2 - 43rd European Society for Medical Oncology Congress (ESMO 2018)

AU - Rini, B. I.

AU - Tannir, N. M.

AU - Escudier, B.

AU - McDermott, D. F.

AU - Grimm, M. O.

AU - Porta, C.

AU - Powles, T.

AU - Kollmannsberger, C. K.

AU - Gurney, H. P.

AU - Tykodi, S. S.

AU - Harrison, M.

AU - Heng, D. Y. C.

AU - Grünwald, V.

AU - Choueiri, T. K.

AU - Mekan, S.

AU - McHenry, M. B.

AU - Hammers, H. J.

AU - Motzer, R. J.

AU - George, S.

N1 - Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2018/10/1

Y1 - 2018/10/1

U2 - 10.1093/annonc/mdy283.084

DO - 10.1093/annonc/mdy283.084

M3 - Meeting abstract

C2 - 32136717

SN - 0923-7534

VL - 29

SP - viii309-viii310

JO - Annals of Oncology

JF - Annals of Oncology

IS - Supplement 8

Y2 - 19 October 2018 through 23 October 2018

ER -